BIOMERICA INC (BMRA) Fundamental Analysis & Valuation

NASDAQ:BMRA • US09061H4065

Current stock price

2.18 USD
0 (0%)
Last:

This BMRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BMRA Profitability Analysis

1.1 Basic Checks

  • BMRA had negative earnings in the past year.
  • BMRA had a negative operating cash flow in the past year.
  • BMRA had negative earnings in each of the past 5 years.
  • BMRA had a negative operating cash flow in each of the past 5 years.
BMRA Yearly Net Income VS EBIT VS OCF VS FCFBMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • With a Return On Assets value of -85.57%, BMRA is not doing good in the industry: 78.61% of the companies in the same industry are doing better.
  • The Return On Equity of BMRA (-125.84%) is worse than 68.98% of its industry peers.
Industry RankSector Rank
ROA -85.57%
ROE -125.84%
ROIC N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
BMRA Yearly ROA, ROE, ROICBMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • BMRA has a worse Gross Margin (4.32%) than 81.28% of its industry peers.
  • In the last couple of years the Gross Margin of BMRA has declined.
  • The Profit Margin and Operating Margin are not available for BMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
BMRA Yearly Profit, Operating, Gross MarginsBMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

5

2. BMRA Health Analysis

2.1 Basic Checks

  • BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BMRA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BMRA has been increased compared to 5 years ago.
  • BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BMRA Yearly Shares OutstandingBMRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
BMRA Yearly Total Debt VS Total AssetsBMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • BMRA has an Altman-Z score of -15.53. This is a bad value and indicates that BMRA is not financially healthy and even has some risk of bankruptcy.
  • BMRA has a worse Altman-Z score (-15.53) than 86.63% of its industry peers.
  • BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.53
ROIC/WACCN/A
WACC8.99%
BMRA Yearly LT Debt VS Equity VS FCFBMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 2.64 indicates that BMRA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.64, BMRA is in line with its industry, outperforming 50.27% of the companies in the same industry.
  • BMRA has a Quick Ratio of 1.59. This is a normal value and indicates that BMRA is financially healthy and should not expect problems in meeting its short term obligations.
  • BMRA has a Quick ratio (1.59) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.64
Quick Ratio 1.59
BMRA Yearly Current Assets VS Current LiabilitesBMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

0

3. BMRA Growth Analysis

3.1 Past

  • BMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.60%, which is quite impressive.
  • BMRA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.81%.
  • BMRA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.51% yearly.
EPS 1Y (TTM)28.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-11.53%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMRA Yearly Revenue VS EstimatesBMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
BMRA Yearly EPS VS EstimatesBMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 -1 -2 -3 -4

0

4. BMRA Valuation Analysis

4.1 Price/Earnings Ratio

  • BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMRA Price Earnings VS Forward Price EarningsBMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMRA Per share dataBMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. BMRA Dividend Analysis

5.1 Amount

  • No dividends for BMRA!.
Industry RankSector Rank
Dividend Yield 0%

BMRA Fundamentals: All Metrics, Ratios and Statistics

BIOMERICA INC

NASDAQ:BMRA (4/28/2026, 8:15:37 PM)

2.18

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength10.56
Industry Growth62.11
Earnings (Last)04-13
Earnings (Next)N/A
Inst Owners2.96%
Inst Owner Change0%
Ins Owners14.06%
Ins Owner Change0%
Market Cap6.74M
Revenue(TTM)4.33M
Net Income(TTM)-4.17M
Analysts85.71
Price TargetN/A
Short Float %2.33%
Short Ratio2.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.56
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.18
EV/EBITDA N/A
EPS(TTM)-1.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS1.4
BVpS1.07
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -85.57%
ROE -125.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.32%
FCFM N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
F-Score3
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.89%
Cap/Sales 0.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.64
Quick Ratio 1.59
Altman-Z -15.53
F-Score3
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)94.83%
Cap/Depr(5y)109.76%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-11.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.93%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMERICA INC / BMRA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMERICA INC?

ChartMill assigns a fundamental rating of 1 / 10 to BMRA.


What is the valuation status for BMRA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMERICA INC (BMRA). This can be considered as Overvalued.


What is the profitability of BMRA stock?

BIOMERICA INC (BMRA) has a profitability rating of 0 / 10.